- Home
- ARGX vs EW Comparison
ARGX vs EW Comparison
Compare ARGX & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARGX
- EW
- Stock Information
- Founded
- ARGX 2008
- EW 1958
- Country
- ARGX Netherlands
- EW United States
- Employees
- ARGX N/A
- EW N/A
- Industry
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- EW Industrial Specialties
- Sector
- ARGX Health Care
- EW Health Care
- Exchange
- ARGX Nasdaq
- EW Nasdaq
- Market Cap
- ARGX 37.3B
- EW 42.5B
- IPO Year
- ARGX 2017
- EW 2000
- Fundamental
- Price
- ARGX $623.82
- EW $74.78
- Analyst Decision
- ARGX Strong Buy
- EW Buy
- Analyst Count
- ARGX 20
- EW 21
- Target Price
- ARGX $634.50
- EW $79.40
- AVG Volume (30 Days)
- ARGX 290.3K
- EW 5.6M
- Earning Date
- ARGX 10-31-2024
- EW 02-04-2025
- Dividend Yield
- ARGX N/A
- EW N/A
- EPS Growth
- ARGX N/A
- EW 193.69
- EPS
- ARGX N/A
- EW 6.89
- Revenue
- ARGX $1,908,659,000.00
- EW $6,314,900,000.00
- Revenue This Year
- ARGX $61.99
- EW N/A
- Revenue Next Year
- ARGX $42.48
- EW $0.91
- P/E Ratio
- ARGX N/A
- EW $28.85
- Revenue Growth
- ARGX 85.56
- EW 24.02
- 52 Week Low
- ARGX $349.86
- EW $58.93
- 52 Week High
- ARGX $644.97
- EW $96.12
- Technical
- Relative Strength Index (RSI)
- ARGX 58.04
- EW 62.35
- Support Level
- ARGX $613.95
- EW $72.29
- Resistance Level
- ARGX $644.97
- EW $74.58
- Average True Range (ATR)
- ARGX 14.33
- EW 1.93
- MACD
- ARGX -0.42
- EW 0.06
- Stochastic Oscillator
- ARGX 50.28
- EW 91.36
About ARGX argenx SE
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.
About EW Edwards Lifesciences Corporation
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter valve technologies, surgical clips, and catheters. The firm derives about 55% of its total sales from outside the US.